Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance

OBJECTIVE: To retrospectively analyze the efficacy and safety of osimertinib combined with anlotinib in the treatment of advanced non‐small‐cell lung cancer (NSCLC) after drug resistance, and to explore the related factors affecting the efficacy. METHODS: The clinical data of 34 patients with advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Mingzhao, Zhao, Jun, Chen, Tong, Hu, Xingsheng, Wang, Lin, Shi, Yuankai, Liu, Yutao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067354/
https://www.ncbi.nlm.nih.gov/pubmed/36843208
http://dx.doi.org/10.1111/1759-7714.14819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067354/
https://www.ncbi.nlm.nih.gov/pubmed/36843208
http://dx.doi.org/10.1111/1759-7714.14819

Ejemplares similares